Pharmaceutical care plan for patients with Parkinson's disease

Parkinson's disease (PD) is a neurodegenerative disease that exhibits motor and non-motor symptoms. It is known that conventional treatment still has many limitations, such as the appearance of various long-term adverse reactions. Considering the new treatments, cannabidiol (CBD) appears as a possibility of pharmacotherapy to PD. The objective of this work was to investigate the possible role of CBD in the treatment of PD, besides evaluating the risks associated with it. In addition, to analyze the conventional pharmacological therapy of PD to create a pharmaceutical care plan. For this, a bibliographic survey using the Pubmed, Medline and Scielo databases was performed. For each of these, specific descriptors and articles from 2010 to 2020 were selected. A total of 888 articles were found, but after reading them, 844 articles were excluded, thus selecting 44 articles. Of these 34 were from Pubmed, 4 from Scielo and 6 from Medline. The drugs used in conventional pharmacotherapy and CBD were analyzed for both motor and non-motor symptoms. Added to this, we proposed a plan of care for the patient with PD.